Clinical—Alimentary TractThiazolidinedione Therapy Is Not Associated With Increased Colonic Neoplasia Risk in Patients With Diabetes Mellitus
Section snippets
Patients and Methods
We conducted 3 retrospective case-control studies nested within the cohort of diabetic patients cared for within the Kaiser Permanente health care system in Northern California (KPNC) during the period 1994 to 1996 and who continue to receive care between 1999 and 2005.
Results
Among the 62,465 patients with type 2 diabetes mellitus, 14,086 had undergone at least 1 lower endoscopy during the study period and met the other inclusion criteria. Cases and controls were relatively similar in all baseline characteristics and across the 3 case-control studies (Table 1). In each case-control study, there were slightly lower percentages of case subjects who were women (eg, 41% cases vs 49% controls in study 1) or users of prescription NSAIDs (eg, 12% cases vs 17% controls in
Discussion
Previous animal studies have suggested that exposure to TZDs can increase or decrease the risk of colonic neoplasia. Because patients with type 2 diabetes mellitus have an increased risk of colorectal cancer, it is important to determine whether the phenomena observed in animal models apply to humans. Two prior studies addressed this question in patients with diabetes. Koro et al did not observe an association between TZD therapy and colon cancer risk but lacked sufficient data to conduct a
References (32)
- et al.
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients
Gastroenterology
(2004) - et al.
Peroxisome proliferator-actived receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice
Gastroenterology
(2003) - et al.
Diabetes mellitus and risk of colorectal cancer: a meta-analysis
J Natl Cancer Inst
(2005) - et al.
Increased blood glucose and insulin, body size, and incident colorectal cancer
J Natl Cancer Inst
(1999) - et al.
Insulin resistance, apoptosis, and colorectal adenoma risk
Cancer Epidemiol Biomarkers Prev
(2005) - et al.
The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers
Carcinogenesis
(1998) - et al.
Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice
Nat Med
(1998) - et al.
Activators of the nuclear receptor PPARγ enhance colon polyp formation
Nat Med
(1998) - et al.
Differentiation and reversal of malignant changes in colon cancer through PPARγ
Nat Med
(1998) - et al.
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus
Coron Artery Dis
(2001)
Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in noninsulin-dependent diabetes mellitus
J Clin Endocrinol Metab
Biology of PPAR γ in cancer: a critical review on existing lacunae
Curr Mol Med
Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats
Cancer Res
APC-dependent suppression of colon carcinogenesis by PPARγ
Proc Natl Acad Sci U S A
Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands
Cancer Res
Cancer risks in thiazolidinedione users compared to other anti-diabetic agents
Pharmacoepidemiol Drug Saf
Cited by (20)
Antidiabetic drugs and risk of cancer
2015, Pharmacological ReportsCitation Excerpt :A minimum of a year-therapy was considered as medication exposure. The results proved no association between TZDs therapy and colonic neoplasia (overall OR = 0.73, 95% CI = 0.57–0.92, patients without anemia OR = 0.97, 95% CI = 0.64–1.49 [74]. In other study, carried out by Lai et al. [53], 19,000 patients with newly diagnosed diabetes were exposed to metformin, TZDs or alpha glucosidase inhibitors.
Positive and negative effects of glitazones in carcinogenesis: Experimental models vs. clinical practice
2014, Pathology Research and PracticeCitation Excerpt :Data on glitazone use and cancer risk in diabetic patients are controversial. Some studies found neither higher nor lower risk of cancer in glitazone users [51,81,88,107]. A retrospective analysis showed that the incidence of lung cancer was 33% lower compared to non-users [60], but the duration of glitazone use was not considered, the participants were almost exclusively men, and the study was not able to account for smoking history, which complicates data interpretation.
Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis
2012, Diabetes and MetabolismCitation Excerpt :In this previous review, we observed an increased risk of bladder cancer associated with TZD use (pooled RR: 1.15, 95%CI 1.04–1.26), which in subgroup analyses was significantly associated with pioglitazone use, but not rosiglitazone use, suggesting that TZD analogues may differ in their association with any given cancer [15]. Aside from the recent focus on bladder cancer, a number of studies report on TZD use and other cancers in people with type 2 diabetes [16–19]. Therefore, our objective was to systematically gather, summarize and appraise evidence from randomized controlled trials (RCTs), cohort and case-control studies to explore the effects of TZDs on the risk of overall and site-specific cancers in people with type 2 diabetes.
The association between metabolic abnormality and endometrial cancer: A large case-control study in China
2010, Gynecologic OncologyCitation Excerpt :We observed a decreased cancer risk in diabetic women with effective medications compared with those without. An effective medical intervention for type 2 diabetes can decrease colon cancer risks [37,38], but we have not found similar reports in endometrial cancer in the English literature by now. A recent epidemiological investigation suggested a protective role of regular physical activity, a common way to control overweight/obesity and diabetes mellitus, on cancer risk [39].
PPARG: A New Independent Marker for Colorectal Cancer Survival
2009, GastroenterologyMetformin use and the risk of colorectal adenoma: A systematic review and meta-analysis
2017, Journal of Gastroenterology and Hepatology (Australia)
The authors disclose the following: Supported by NIH grant CA102599. Drs Lewis, Habel, Ferrara, and Quesenberry have received research funding from Takeda. Dr Lewis has received research support from GlaxoSmithKline. Drs Habel and Ferrara have received research support from Eli Lilly. Dr Habel has also received research support from Merck.